C Andrew Combs, MD
Maternal & Fetal Medicine · Campbell
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 3
- 2 carriers
- Office
- 1
Offices
1 location
Plans that list them
3 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Combs’s office at (408) 371-7111 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
3 of 3 plans
| Anthem Full Dual Advantage Aligned (HMO D-SNP) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Medicare Advantage (HMO-POS) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Prime (HMO-POS) | Anthem Blue Cross Partnership Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence G63157 · Current
Licensed to practise in California · since 1988 · expires 2027-11-30 · University of Washington School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Obstetrics and Gynecology - Maternal and Fetal Medicine
- American Board of Obstetrics and Gynecology - Obstetrics and Gynecology
Medicaid work
$38,924 in 2024
Medicaid paid $38,924 for 398 billed services this clinician did in 2024, up to 53 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Ultrasound, pregnant uterus, real time with image documentation, follow-up (eg, re-evaluation of fetal size by measuring standard growth parameters and amniotic fluid volume, re-evaluation of organ system(s) suspected or confirmed to be abnormal on a previous scan), transabdominal approach, per fetus | 209 | $14,509 |
| Ultrasound, pregnant uterus, real time with image documentation, first trimester fetal nuchal translucency measurement, transabdominal or transvaginal approach; single or first gestation | 106 | $13,482 |
| Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation plus detailed fetal anatomic examination, transabdominal approach; single or first gestation | 51 | $8,618 |
| Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, first trimester (< 14 weeks 0 days), transabdominal approach; single or first gestation | 19 | $1,320 |
| OFFICE/OP CONSLTJ NEW/EST PT LOW MDM 30 MINUTES | 13 | $996 |
| 2024 | 398 | 5 | 53 | $38,924 |
| 2022 | 180 | 4 | 18 | $5,642 |
| 2021 | 449 | 5 | 31 | $12,730 |
| 2020 | 519 | 5 | 26 | $16,992 |
| 2019 | 416 | 5 | 27 | $11,945 |
| 2018 | 576 | 4 | 27 | $28,554 |
See the largest Medicaid services in earlier years
2022
| Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation plus detailed fetal anatomic examination, transabdominal approach; single or first gestation | 48 | $3,383 |
| Ultrasound, pregnant uterus, real time with image documentation, follow-up (eg, re-evaluation of fetal size by measuring standard growth parameters and amniotic fluid volume, re-evaluation of organ system(s) suspected or confirmed to be abnormal on a previous scan), transabdominal approach, per fetus | 71 | $1,305 |
| Ultrasound, pregnant uterus, real time with image documentation, transvaginal | 28 | $954 |
| Additional supplies, materials, and clinical staff time over and above those usually included in an office visit or other non-facility service(s), when performed during a Public Health Emergency, as defined by law, due to respiratory-transmitted infectious disease | 33 | $0 |
2021
| Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation plus detailed fetal anatomic examination, transabdominal approach; single or first gestation | 90 | $6,414 |
| Ultrasound, pregnant uterus, real time with image documentation, follow-up (eg, re-evaluation of fetal size by measuring standard growth parameters and amniotic fluid volume, re-evaluation of organ system(s) suspected or confirmed to be abnormal on a previous scan), transabdominal approach, per fetus | 149 | $3,724 |
| Ultrasound, pregnant uterus, real time with image documentation, transvaginal | 97 | $2,286 |
| FETAL NON-STRESS TEST | 34 | $306 |
| Additional supplies, materials, and clinical staff time over and above those usually included in an office visit or other non-facility service(s), when performed during a Public Health Emergency, as defined by law, due to respiratory-transmitted infectious disease | 79 | $0 |
2020
| Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation plus detailed fetal anatomic examination, transabdominal approach; single or first gestation | 141 | $9,367 |
| Ultrasound, pregnant uterus, real time with image documentation, follow-up (eg, re-evaluation of fetal size by measuring standard growth parameters and amniotic fluid volume, re-evaluation of organ system(s) suspected or confirmed to be abnormal on a previous scan), transabdominal approach, per fetus | 165 | $3,601 |
| Ultrasound, pregnant uterus, real time with image documentation, transvaginal | 137 | $3,464 |
| FETAL NON-STRESS TEST | 57 | $550 |
| Additional supplies, materials, and clinical staff time over and above those usually included in an office visit or other non-facility service(s), when performed during a Public Health Emergency, as defined by law, due to respiratory-transmitted infectious disease | 19 | $11 |
2019
| Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation plus detailed fetal anatomic examination, transabdominal approach; single or first gestation | 105 | $7,100 |
| Ultrasound, pregnant uterus, real time with image documentation, follow-up (eg, re-evaluation of fetal size by measuring standard growth parameters and amniotic fluid volume, re-evaluation of organ system(s) suspected or confirmed to be abnormal on a previous scan), transabdominal approach, per fetus | 156 | $3,118 |
| FETAL NON-STRESS TEST | 97 | $888 |
| Ultrasound, pregnant uterus, real time with image documentation, transvaginal | 44 | $584 |
| ANTEPARTUM CARE ONLY 4-6 VISITS | 14 | $254 |
2018
| Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation plus detailed fetal anatomic examination, transabdominal approach; single or first gestation | 141 | $14,985 |
| Ultrasound, pregnant uterus, real time with image documentation, transvaginal | 135 | $6,434 |
| Ultrasound, pregnant uterus, real time with image documentation, follow-up (eg, re-evaluation of fetal size by measuring standard growth parameters and amniotic fluid volume, re-evaluation of organ system(s) suspected or confirmed to be abnormal on a previous scan), transabdominal approach, per fetus | 220 | $6,108 |
| FETAL NON-STRESS TEST | 80 | $1,028 |
Money from drug and device companies
$12 in 2020
A payment is not proof that care is biased.
| Hologic | Fetal Fibronectin | $12 | 1 payment
|
See the published payment
| Hologic | Meals · 2020-02-06 | Fetal Fibronectin | $12 |
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| ROCHE SEQUENCING SOLUTIONS, INC. · Harmony Test Related Products · 2020 | Their institution | $8,381 |
| AMAG Pharmaceuticals, Inc. · A Phase 2b/3a, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy and Safety of Amag-423, A Digoxin Immune Fab, in Antepartum Subjects With Severe Preeclampsia · 2020 | Their institution | $5,000 |
| ROCHE SEQUENCING SOLUTIONS, INC. · 2021 | Their institution | $1,857 |
| AMAG Pharmaceuticals, Inc. · A Phase 2b3a, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy and Safety of Amag-423, A Digoxin Immune Fab, in Antepartum Subjects With Severe Preeclampsia · 2019 | This clinician | $749 |
| AMAG Pharmaceuticals, Inc. · A Phase 2b3a, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy and Safety of Amag-423, A Digoxin Immune Fab, in Antepartum Subjects With Severe Preeclampsia · 2019 | Their institution | $353 |
Professional record
- NPI
- 1134181480
- Licence
- CA G63157California G63157: Current · expires 2027-11-30
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207VM0101X (207VM0101X)
- Mailing address
- 900 E Hamilton Ave, Obstetrix, Campbell, CA, 95008
- NPI first listed
- 2006-04-03
- NPI last updated
- 2007-07-08
This is when the NPI record was last certified, not a medical board exam.